Marshall HS, McMillan M, Koehler AP, et al. - In this study, researchers tried to find out the effect of Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. They applied cluster randomization to select, according to school, students in years 10 to 12 (age, 15 to 18 years) in South Australia to receive 4CMenB vaccination either at baseline (intervention) or at 12 months (control). During April through June 2017, they selected a total of 237 schools including a total of 24,269 students in years 10 and 11 and 10,220 students in year 12. No difference was found in the prevalence of carriage of disease-causing N. meningitidis between the vaccination group and the control group at 12 months. No significant differences were obtained in the secondary carriage outcomes. The results revealed that the 4CMenB vaccine had no discernible effect on the carriage of disease-causing meningococci, including group B among Australian adolescents.